|
US5766920A
(en)
*
|
1982-08-11 |
1998-06-16 |
Cellcor, Inc. |
Ex vivo activation of immune cells
|
|
US5192537A
(en)
*
|
1984-03-30 |
1993-03-09 |
Cellcor Inc. |
Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
|
|
IL69686A
(en)
*
|
1983-09-11 |
1988-03-31 |
Yeda Res & Dev |
Compositions containing cell membrane proteins and process for their preparation
|
|
US4883662A
(en)
*
|
1984-04-10 |
1989-11-28 |
Clinical Biotechnologies, Inc. |
Method of increasing natural killer cell population of cancer patients
|
|
US5837229A
(en)
*
|
1985-02-05 |
1998-11-17 |
Chiron Corporation |
Uses of recombinant colony stimulating factor-1
|
|
US5556620A
(en)
*
|
1985-02-05 |
1996-09-17 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor-1 to enhance wound healing
|
|
US5308626A
(en)
*
|
1985-06-28 |
1994-05-03 |
Toni N. Mariani |
Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
|
|
US4902288A
(en)
*
|
1985-12-03 |
1990-02-20 |
Marylou Ingram |
Implantable immunotherapy system using stimulated cells
|
|
JP2529321B2
(ja)
*
|
1986-04-28 |
1996-08-28 |
エンドトロニックス インコーポレーテッド |
白血球を培養する方法
|
|
US5002879A
(en)
*
|
1986-05-06 |
1991-03-26 |
Merrell Dow Pharmaceuticals |
Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
|
|
US4937194A
(en)
*
|
1986-05-12 |
1990-06-26 |
Baxter International Inc. |
Method for metering nutrient media to cell culture containers
|
|
US4829002A
(en)
*
|
1986-05-12 |
1989-05-09 |
Baxter International Inc. |
System for metering nutrient media to cell culture containers and method
|
|
US4971795A
(en)
*
|
1986-07-08 |
1990-11-20 |
Biomira, Inc. |
Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype
|
|
WO1988000970A2
(en)
*
|
1986-08-08 |
1988-02-11 |
Regents Of The University Of Minnesota |
Method of culturing leukocytes
|
|
ATE107861T1
(de)
*
|
1986-09-19 |
1994-07-15 |
Oncogen |
Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.
|
|
US4861589A
(en)
*
|
1987-03-23 |
1989-08-29 |
Trustees Of Boston University |
Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
|
|
US4808151A
(en)
*
|
1987-04-27 |
1989-02-28 |
E. I. Du Pont De Nemours And Company |
Simplified method for the preparation of human lymphokine activated killer cells
|
|
EP0331716A4
(de)
*
|
1987-09-22 |
1990-02-06 |
Arthur Allen Vandenbark |
Verfahren zur selektiven modulation der expression und der funktion einer zellulären oberflächendeterminante und auf diese weise produzierte neue menschliche zellen.
|
|
US5041289A
(en)
*
|
1987-11-13 |
1991-08-20 |
Becton Dickinson And Company |
Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
|
|
AU2925789A
(en)
*
|
1987-12-17 |
1989-07-19 |
Browning's Clinical Pathology Services Limited |
Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
|
|
US5057423A
(en)
*
|
1987-12-18 |
1991-10-15 |
University Of Pittsburgh |
Method for the preparation of pure LAK-active lymphocytes
|
|
US5066489A
(en)
*
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
|
US5120525A
(en)
*
|
1988-03-29 |
1992-06-09 |
Immunomedics, Inc. |
Radiolabeled antibody cytotoxic therapy of cancer
|
|
US20030232010A2
(en)
*
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
|
CA1329119C
(en)
*
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Cytotoxic therapy
|
|
US5278143A
(en)
*
|
1988-04-25 |
1994-01-11 |
Trustees Of Boston University |
Prophylactic and therapeutic methods for treating interleukin-mediated edemas
|
|
FR2635527B1
(fr)
*
|
1988-07-28 |
1992-06-12 |
Roussel Uclaf |
Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
|
|
AU4525589A
(en)
*
|
1988-10-27 |
1990-05-14 |
Regents Of The University Of Minnesota |
Liposome immunoadjuvants containing il-2
|
|
GB8826298D0
(en)
*
|
1988-11-10 |
1988-12-14 |
Williams N S |
Production of lak cells compositions containing them & their use in cancer therapy
|
|
CA1340565C
(en)
*
|
1989-06-29 |
1999-05-25 |
Thomas B. Okarma |
Device and process for cell capture and recovery
|
|
US6143508A
(en)
*
|
1989-06-29 |
2000-11-07 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Device and process for cell capture and recovery
|
|
US5108760A
(en)
*
|
1989-07-21 |
1992-04-28 |
Terumo Corporation |
Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides
|
|
US5126132A
(en)
*
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
EP0491851A4
(en)
*
|
1989-09-14 |
1993-02-17 |
Cellco, Inc. |
Method for the production of in vitro expanded lymphoid cells for use in adoptive immunotherapy
|
|
JPH0728732B2
(ja)
*
|
1990-04-17 |
1995-04-05 |
日本石油株式会社 |
動物細胞増殖促進剤及び無血清培地
|
|
US5344755A
(en)
*
|
1990-04-21 |
1994-09-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for detecting immune system dysfunction in asymptomatic, HIV-scropositive individuals
|
|
US5766897A
(en)
*
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
|
US20030064480A1
(en)
*
|
1990-06-28 |
2003-04-03 |
Leander Lauffer |
Fusion proteins with immunoglobulin portions, the preparation and use thereof
|
|
US5229115A
(en)
*
|
1990-07-26 |
1993-07-20 |
Immunex Corporation |
Adoptive immunotherapy with interleukin-7
|
|
WO1992012726A1
(en)
*
|
1991-01-16 |
1992-08-06 |
Schering Corporation |
Use of interleukin-10 in adoptive immunotherapy of cancer
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US5843728A
(en)
*
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
|
US5912170A
(en)
*
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
|
US5725855A
(en)
*
|
1991-04-05 |
1998-03-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
|
|
WO1992017567A1
(en)
*
|
1991-04-05 |
1992-10-15 |
Regents Of The University Of Minnesota |
Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
|
|
US5199942A
(en)
*
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
IE922233A1
(en)
*
|
1991-07-10 |
1993-01-13 |
Augusto C Ochoa |
Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
|
|
DE69232722T2
(de)
*
|
1991-08-23 |
2002-12-05 |
The Board Of Regents Of The University Of Nebraska, Lincoln |
Verfahren und zusammensetzungen für zelluläre reprogrammierung
|
|
JPH07502734A
(ja)
*
|
1991-12-31 |
1995-03-23 |
ザイモジェネティクス，インコーポレイティド |
血液損失を減少する方法および組成物
|
|
US5296353A
(en)
*
|
1992-04-06 |
1994-03-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Evaluation and treatment of patients with progessive immunosuppression
|
|
US5556763A
(en)
*
|
1992-04-06 |
1996-09-17 |
United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Evaluation and treatment of patients with progressive immunosuppression
|
|
US5229109A
(en)
*
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
TW381026B
(en)
*
|
1993-01-13 |
2000-02-01 |
Schering Corp |
Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
|
|
US5670352A
(en)
*
|
1993-03-18 |
1997-09-23 |
Behringwerke Aktiengesellschaft |
Stable growth transformation of human T-lymphocytes by Herpesvirus saimiri (H. saimiri) subgroup C
|
|
AU6989094A
(en)
*
|
1993-05-27 |
1994-12-20 |
Entremed, Inc |
Compositions and methods for treating cancer and hyperproliferative disorders
|
|
US5536642A
(en)
*
|
1993-09-09 |
1996-07-16 |
Barbera-Guillem; Emilio |
Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
|
|
US5750119A
(en)
*
|
1994-01-13 |
1998-05-12 |
Mount Sinai School Of Medicine Of The City University Of New York |
Immunotherapeutic stress protein-peptide complexes against cancer
|
|
US5997873A
(en)
*
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
|
US5961979A
(en)
|
1994-03-16 |
1999-10-05 |
Mount Sinai School Of Medicine Of The City University Of New York |
Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
|
|
IL112969A
(en)
*
|
1994-03-17 |
2001-05-20 |
Baxter Int |
Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
|
|
US5709995A
(en)
*
|
1994-03-17 |
1998-01-20 |
The Scripps Research Institute |
Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
|
|
JPH10504304A
(ja)
*
|
1994-08-08 |
1998-04-28 |
マキシム ファーマシューティカルズ，インコーポレイテッド |
ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強
|
|
WO1996010419A2
(en)
*
|
1994-10-03 |
1996-04-11 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer |
Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
|
|
US6045802A
(en)
*
|
1994-10-03 |
2000-04-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
|
|
US5935847A
(en)
*
|
1994-10-28 |
1999-08-10 |
Baxter International Inc. |
Multilayer gas-permeable container for the culture of adherent and non-adherent cells
|
|
US6297046B1
(en)
|
1994-10-28 |
2001-10-02 |
Baxter International Inc. |
Multilayer gas-permeable container for the culture of adherent and non-adherent cells
|
|
US7361332B2
(en)
|
1995-03-17 |
2008-04-22 |
The Regents Of The University Of California |
Treating tumors using implants comprising combinations of allogeneic cells
|
|
US6391404B1
(en)
|
1995-06-07 |
2002-05-21 |
Baxter International Inc. |
Coextruded multilayer film materials and containers made therefrom
|
|
US6024220A
(en)
*
|
1995-06-07 |
2000-02-15 |
Baxter International Inc. |
Encapsulated seam for multilayer materials
|
|
US5627070A
(en)
*
|
1995-07-26 |
1997-05-06 |
Celltherapy, Inc. |
Cell growing device for in vitro cell population expansion
|
|
US20020182730A1
(en)
*
|
1995-07-26 |
2002-12-05 |
Micheal L. Gruenberg |
Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
|
|
US5935576A
(en)
|
1995-09-13 |
1999-08-10 |
Fordham University |
Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
|
|
US5837251A
(en)
*
|
1995-09-13 |
1998-11-17 |
Fordham University |
Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
|
|
US5985270A
(en)
*
|
1995-09-13 |
1999-11-16 |
Fordham University |
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
|
|
CA2243235C
(en)
|
1996-01-17 |
2010-08-10 |
Imperial College Innovations Limited |
Immunotherapy using cytotoxic t lymphocytes (ctl)
|
|
JP2002512501A
(ja)
|
1996-07-03 |
2002-04-23 |
メリアル インコーポレイテッド |
外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
|
|
US6130087A
(en)
*
|
1996-10-07 |
2000-10-10 |
Fordham University |
Methods for generating cytotoxic T cells in vitro
|
|
US5830464A
(en)
*
|
1997-02-07 |
1998-11-03 |
Fordham University |
Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
|
|
US6017540A
(en)
*
|
1997-02-07 |
2000-01-25 |
Fordham University |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
|
|
US5981472A
(en)
*
|
1997-02-21 |
1999-11-09 |
Dx/Ibr Corporation |
Methods for treating diseases
|
|
US6884414B1
(en)
|
1997-04-30 |
2005-04-26 |
Mount Sinai School Of Medicine Of New York University |
Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
|
|
US6872518B2
(en)
*
|
1997-09-22 |
2005-03-29 |
University Of Rochester |
Methods for selecting polynucleotides encoding T cell epitopes
|
|
PT1037927E
(pt)
|
1997-12-08 |
2004-10-29 |
Emd Lexigen Res Ct Corp |
Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
|
|
US5948646A
(en)
|
1997-12-11 |
1999-09-07 |
Fordham University |
Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
|
|
ES2439014T3
(es)
*
|
1998-02-20 |
2014-01-21 |
The University Of Miami |
Complejo de péptido antigénico-proteína de choque térmico modificada
|
|
AU2873999A
(en)
|
1998-02-24 |
1999-09-06 |
Sisters Of Providence In Oregon |
Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
|
|
US6790604B1
(en)
|
1998-05-12 |
2004-09-14 |
Stefan A. Cohen |
Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
|
|
EP1089757B1
(de)
|
1998-06-17 |
2009-04-22 |
IDM Pharma, Inc. |
Hla-bindende peptide und ihre verwendungen
|
|
US6929791B2
(en)
|
1998-07-16 |
2005-08-16 |
Institut Pasteur |
Peptides of IL-2 and derivatives thereof
|
|
US6168785B1
(en)
*
|
1998-07-16 |
2001-01-02 |
Institut Pasteur |
Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
|
|
US20020092987A1
(en)
*
|
1998-09-05 |
2002-07-18 |
Taehee Cho |
Photo detect device using quantum dots and materialization method thereof
|
|
US6451316B1
(en)
|
1998-10-05 |
2002-09-17 |
University Of Conneticut Health Center |
Methods for generating antigen-reactive T cells in vitro
|
|
US7807377B2
(en)
|
1998-10-20 |
2010-10-05 |
Salvatore Albani |
Method of isolating antigen-specific T cells employing artificial antigen presenting cells
|
|
JP2002527467A
(ja)
|
1998-10-20 |
2002-08-27 |
サルバトーレ・アルバーニ |
抗原特異的ｔ細胞の単離、定量、特徴づけおよび調節方法
|
|
US6787154B2
(en)
*
|
1998-10-20 |
2004-09-07 |
Salvatore Albani |
Artificial antigen presenting cells
|
|
HK1044040A1
(zh)
|
1998-11-16 |
2002-10-04 |
德克萨斯州立大学董事会 |
Hiv-特异的t-细胞诱导
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
BR0013231A
(pt)
|
1999-08-09 |
2002-07-23 |
Lexigen Pharm Corp |
Complexos citocina-anticorpo múltiplos
|
|
US20040266834A1
(en)
*
|
1999-10-14 |
2004-12-30 |
Copland John A. |
Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
|
|
EP1228214A2
(de)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietinformen mit verbesserten eigenschaften
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
JP2003528605A
(ja)
*
|
2000-03-28 |
2003-09-30 |
ユニヴァーシティー オヴ ロチェスター |
ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
|
|
US20030194696A1
(en)
*
|
2000-03-28 |
2003-10-16 |
University Of Rochester |
Methods of producing a library and methods of selecting polynucleotides of interest
|
|
AU6669401A
(en)
|
2000-06-02 |
2001-12-11 |
Univ Connecticut Health Ct |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
|
JP5390055B2
(ja)
|
2000-06-29 |
2014-01-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
|
|
CA2425648A1
(en)
|
2000-10-19 |
2002-04-19 |
Epimmune Inc. |
Hla class i and ii binding peptides and their uses
|
|
DE60032949T2
(de)
*
|
2000-11-30 |
2007-10-25 |
Imperial Innovations Ltd. |
Immuntherapeutische methoden und moleküle
|
|
US7919467B2
(en)
*
|
2000-12-04 |
2011-04-05 |
Immunotope, Inc. |
Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
|
|
EP1356048A2
(de)
|
2000-12-04 |
2003-10-29 |
Argonex Pharmaceuticals |
Zytotoxisch t-lymphozyte induzierende immunogene zur krebsvorbeugung,behandlung, und diagnose
|
|
US6855925B2
(en)
*
|
2001-02-14 |
2005-02-15 |
Picoliter Inc. |
Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
|
|
HUP0303428A2
(hu)
|
2001-03-07 |
2004-01-28 |
Merck Patent Gmbh. |
Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
|
|
FR2821947B1
(fr)
*
|
2001-03-12 |
2003-05-16 |
Canon Kk |
Procede et dispositif de validation de parametres definissant une image
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
KR100900166B1
(ko)
|
2001-05-03 |
2009-06-02 |
메르크 파텐트 게엠베하 |
재조합 종양 특이적 항체 및 이들의 용도
|
|
PL375043A1
(en)
*
|
2001-08-20 |
2005-11-14 |
University Of Connecticut Health Center |
Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin, useful for the treatment of cancer and infectious disease
|
|
WO2003024312A2
(en)
*
|
2001-09-17 |
2003-03-27 |
Valeocyte Therapies Llc |
Cell therapy system
|
|
US20030134341A1
(en)
*
|
2001-09-19 |
2003-07-17 |
Medcell Biologics, Llc. |
Th1 cell adoptive immunotherapy
|
|
US20030134415A1
(en)
*
|
2001-09-19 |
2003-07-17 |
Gruenberg Micheal L. |
Th1 cell adoptive immunotherapy
|
|
RU2201762C1
(ru)
*
|
2001-10-09 |
2003-04-10 |
Свадовский Александр Игоревич |
Способ лечения внутримозговой опухоли головного мозга
|
|
WO2003044183A1
(en)
*
|
2001-11-22 |
2003-05-30 |
Medigenes |
Interleukin-2 gene transferred lymphokine activated killer cells
|
|
ATE542137T1
(de)
|
2001-12-04 |
2012-02-15 |
Merck Patent Gmbh |
Immunocytokine mit modulierter selektivität
|
|
US20040236514A1
(en)
*
|
2001-12-13 |
2004-11-25 |
Lee Stephen C. |
Controlling distribution of epitopes in polypeptide sequences
|
|
WO2003104428A2
(en)
|
2002-01-21 |
2003-12-18 |
Vaccinex, Inc. |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
|
US20030175272A1
(en)
*
|
2002-03-07 |
2003-09-18 |
Medcell Biologics, Inc. |
Re-activated T-cells for adoptive immunotherapy
|
|
US8034334B2
(en)
*
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
US9809654B2
(en)
*
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
|
CN100432105C
(zh)
|
2002-12-17 |
2008-11-12 |
默克专利有限公司 |
与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
|
|
CA2514500A1
(en)
*
|
2003-02-20 |
2004-09-10 |
University Of Connecticut Health Center |
Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
|
|
US7638122B2
(en)
*
|
2003-03-07 |
2009-12-29 |
University Of South Florida |
Stat3 antagonists and their use as vaccines against cancer
|
|
US20040242676A1
(en)
*
|
2003-05-30 |
2004-12-02 |
Alessi Thomas R. |
Method of mitigating the adverse effects of IL-2
|
|
CA2537759C
(en)
|
2003-09-05 |
2015-03-24 |
Oregon Health & Science University |
Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
|
|
EP2289547B1
(de)
*
|
2003-09-12 |
2015-12-16 |
Agenus Inc. |
Impfstoff zur Behandlung und Prävention der Herpes Simplex-Virusinfektion
|
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
AU2004299457B2
(en)
|
2003-12-12 |
2011-03-24 |
Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
|
|
US7838503B2
(en)
*
|
2005-06-15 |
2010-11-23 |
Children's Medical Center Corporation |
Methods for extending the replicative lifespan of cells
|
|
US20090162374A1
(en)
*
|
2005-09-14 |
2009-06-25 |
Geraghty Daniel E |
Specific removal of activated immune cells
|
|
US20070248628A1
(en)
*
|
2005-12-06 |
2007-10-25 |
Keller Lorraine H |
Immunogens in cancer stem cells
|
|
EP1998800A2
(de)
|
2006-01-18 |
2008-12-10 |
University Of Chicago |
Zusammensetzungen und verfahren in verbindung mit stayphylokokken-bakterienproteinen
|
|
US7993638B2
(en)
|
2006-03-01 |
2011-08-09 |
Janssen Pharmaceutica Nv |
Cancer treatment combining lymphodepleting agent with CTLs and cytokines
|
|
US20080107668A1
(en)
*
|
2006-08-30 |
2008-05-08 |
Immunotope, Inc. |
Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
|
|
US8129184B2
(en)
|
2006-09-26 |
2012-03-06 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
|
US8871211B2
(en)
|
2006-09-28 |
2014-10-28 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
|
CA2665568C
(en)
|
2006-10-04 |
2018-01-09 |
Janssen Pharmaceutica, N.V. |
Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
JP5357782B2
(ja)
*
|
2007-02-21 |
2013-12-04 |
バクシネックス インコーポレーティッド |
抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
|
|
WO2008137705A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Boris Skurkovich |
Prevention of cancers by immunization
|
|
JP5658564B2
(ja)
|
2007-08-31 |
2015-01-28 |
ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ |
ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
|
|
US9181329B2
(en)
|
2007-08-31 |
2015-11-10 |
The University Of Chicago |
Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
|
|
ES2666667T3
(es)
|
2008-01-29 |
2018-05-07 |
Fred Hutchinson Cancer Research Center |
Identificación de células T CD8+ que son CD161 hi y/o IL-18R (alfa) hi y tienen una capacidad de evacuación rápida de fármacos
|
|
EP2257301B1
(de)
|
2008-03-03 |
2014-01-22 |
The University of Miami |
Auf allogenen krebszellen basierende immuntherapie
|
|
AU2009226077B2
(en)
|
2008-03-20 |
2012-04-19 |
University Of Miami |
Heat shock protein gp96 vaccination and methods of using same
|
|
EP2300023A2
(de)
*
|
2008-05-16 |
2011-03-30 |
Genelux Corporation |
Mikroorganismen zur prävention und behandlung von neoplasien neben einer zelltherapie
|
|
US8758765B2
(en)
*
|
2008-07-29 |
2014-06-24 |
The University Of Chicago |
Compositions and methods related to Staphylococcal bacterium proteins
|
|
PL2328923T3
(pl)
*
|
2008-09-02 |
2016-06-30 |
Cedars Sinai Medical Center |
Epitopy CD133
|
|
WO2010042481A1
(en)
|
2008-10-06 |
2010-04-15 |
University Of Chicago |
Compositions and methods related to bacterial eap, emp, and/or adsa proteins
|
|
WO2010060026A1
(en)
*
|
2008-11-21 |
2010-05-27 |
University Of Miami |
Hiv/siv vaccines for the generation of mucosal and systemic immunity
|
|
AU2010203451B2
(en)
|
2009-01-08 |
2016-06-30 |
Albert Einstein College Of Medicine, Inc. |
Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
|
|
EP3281947B1
(de)
|
2009-04-03 |
2020-02-12 |
The University of Chicago |
Zusammensetzungen und verfahren in verbindung mit protein-a (spa)-varianten
|
|
ES2618573T3
(es)
|
2009-05-07 |
2017-06-21 |
ImmunoCellular Therapeutics,Ltd |
Epítopos de CD133
|
|
EP2470200B1
(de)
|
2009-08-26 |
2017-03-15 |
Immunotope, Inc. |
Zytotoxische t-lymphozyten-induzierende immunogene zur prävention, behandlung und diagnose von krebs
|
|
US8075895B2
(en)
|
2009-09-22 |
2011-12-13 |
Janssen Pharmaceutica N.V. |
Identification of antigenic peptides from multiple myeloma cells
|
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
EP2555794A4
(de)
|
2010-04-05 |
2014-01-15 |
Univ Chicago |
Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
|
|
KR102095670B1
(ko)
|
2010-05-14 |
2020-03-31 |
더 제너럴 하스피톨 코포레이션 |
종양 특이적 신생항원을 확인하는 조성물 및 방법
|
|
ES2655701T3
(es)
|
2010-07-02 |
2018-02-21 |
The University Of Chicago |
Composiciones y métodos relacionados con variantes de la proteína A (SpA)
|
|
JP5793194B2
(ja)
|
2010-09-09 |
2015-10-14 |
ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ |
感染防御ブドウ球菌抗原が関与する方法および組成物
|
|
NZ723974A
(en)
|
2010-10-27 |
2017-03-31 |
Baylor College Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
|
US9987308B2
(en)
|
2011-03-23 |
2018-06-05 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
EP2505640A1
(de)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
|
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
|
WO2013003579A1
(en)
|
2011-06-29 |
2013-01-03 |
Immunotope, Inc. |
Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
|
|
EP2755679B1
(de)
|
2011-09-13 |
2017-08-02 |
Immunotope, Inc. |
Zytotoxische t-lymphozyten-induzierende immunogene zur prävention, behandlung und diagnose von krebs
|
|
EP2755487B1
(de)
|
2011-09-16 |
2018-12-19 |
Baylor College Of Medicine |
Gegen die tumormikroumgebung gerichtete manipulierte nkt-zellen
|
|
WO2013049856A2
(en)
|
2011-09-30 |
2013-04-04 |
Hare Joshue M |
Renal stem cells isolated from kidney
|
|
HRP20201127T1
(hr)
|
2012-04-26 |
2020-11-27 |
University Of Chicago |
Antigeni stafilokokne koagulaze i metode primjene istih
|
|
EP4282419A1
(de)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
|
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
|
US20140234351A1
(en)
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd. |
Cancer vaccines and vaccination methods
|
|
BR112015025460B1
(pt)
|
2013-04-07 |
2024-01-02 |
The Broad Institute, Inc. |
Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
|
|
EP3974520A1
(de)
|
2013-05-14 |
2022-03-30 |
Board of Regents, The University of Texas System |
Menschliche anwendung manipulierter chimärer antigen-rezeptor (car)-t-zellen
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
NZ721908A
(en)
|
2013-12-20 |
2022-12-23 |
Massachusetts Gen Hospital |
Combination therapy with neoantigen vaccine
|
|
US10155036B2
(en)
|
2014-02-28 |
2018-12-18 |
Emergex Vaccines Holding Ltd. |
MHC class I associated peptides for prevention and treatment of hepatitis B virus infection
|
|
US20170158749A1
(en)
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
IL313845A
(en)
|
2014-04-23 |
2024-08-01 |
Juno Therapeutics Inc |
Methods for enriching or producing immune cell populations for adoptive therapy
|
|
WO2015164740A1
(en)
|
2014-04-24 |
2015-10-29 |
Board Of Regents, The University Of Texas System |
Application of induced pluripotent stem cells to generate adoptive cell therapy products
|
|
KR102211120B1
(ko)
|
2014-05-15 |
2021-02-03 |
내셔널 유니버시티 오브 싱가포르 |
변형된 천연 살해 세포 및 그의 용도
|
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
CN117427091A
(zh)
|
2014-10-20 |
2024-01-23 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗中的给药的组合物和方法
|
|
WO2016073629A1
(en)
|
2014-11-05 |
2016-05-12 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
KR20170075785A
(ko)
|
2014-11-05 |
2017-07-03 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포
|
|
CN113736828A
(zh)
|
2014-11-05 |
2021-12-03 |
朱诺治疗学股份有限公司 |
用于转导及细胞处理的方法
|
|
WO2016090190A1
(en)
|
2014-12-03 |
2016-06-09 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
|
EP4636401A2
(de)
|
2014-12-19 |
2025-10-22 |
The Broad Institute, Inc. |
Verfahren zur profilierung des t-zell-rezeptor-repertoirs
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
|
AR103442A1
(es)
|
2015-01-16 |
2017-05-10 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígenos quiméricos específicos de ror1
|
|
KR20170109582A
(ko)
|
2015-02-06 |
2017-09-29 |
히트 바이오로직스, 인코퍼레이티드 |
벡터 공동 발현 백신 및 공동 자극 분자
|
|
CA2977818A1
(en)
|
2015-03-11 |
2016-09-15 |
Board Of Regents, The University Of Texas System |
Transposase polypeptides and uses thereof
|
|
EP3270937A4
(de)
|
2015-03-26 |
2018-09-12 |
The Trustees Of Dartmouth College |
Fragmente zur bindung des anti-mica-antigens, fusionsmoleküle, expressionszellen und verfahren zur verwendung
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
|
EP3294324A1
(de)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Impfstoffe zur behandlung und prävention von krebs
|
|
CA2986235A1
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute, Inc. |
Shared neoantigens
|
|
MA43344A
(fr)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics Inc |
Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
|
|
TWI750122B
(zh)
|
2015-06-09 |
2021-12-21 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
CA2997749A1
(en)
|
2015-09-09 |
2017-03-16 |
Immune Design Corp. |
Ny-eso-1 specific tcrs and methods of use thereof
|
|
WO2017046335A1
(en)
|
2015-09-18 |
2017-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
|
|
PH12018500645B1
(en)
|
2015-09-24 |
2022-10-21 |
Abvitro Llc |
Hiv antibody compositions and methods of use
|
|
US10928392B2
(en)
|
2015-09-25 |
2021-02-23 |
Abvitro Llc |
High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
|
|
US11365391B2
(en)
|
2015-09-28 |
2022-06-21 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
|
EP3355918B1
(de)
|
2015-09-28 |
2021-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Biofunktionalisierte nanopartikel und verwendungen davon in adoptiver zelltherapie
|
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
|
CN108474791B
(zh)
|
2015-10-22 |
2022-07-08 |
朱诺治疗学有限公司 |
培养细胞的方法及用于该方法的试剂盒和设备
|
|
HK1258932A1
(zh)
|
2015-10-22 |
2019-11-22 |
Juno Therapeutics Gmbh |
用於转导的方法、反应剂盒、反应剂和设备
|
|
US11466253B2
(en)
|
2015-10-22 |
2022-10-11 |
Juno Therapeutics Gmbh |
Methods for culturing cells and kits and apparatus for same
|
|
EP3368075B1
(de)
|
2015-10-27 |
2020-01-29 |
Board of Regents, The University of Texas System |
Chimärische antigennrezeptoren (cars) und ihre verwendungen
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
EP3368689B1
(de)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Zusammensetzungen zur modulierung von immunantworten unter verwendung von immunzellgensignaturen
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
CN108884140B
(zh)
|
2015-12-03 |
2022-10-25 |
朱诺治疗学股份有限公司 |
修饰的嵌合受体及相关组合物和方法
|
|
US20200297760A1
(en)
|
2015-12-03 |
2020-09-24 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
|
MA43377A
(fr)
|
2015-12-04 |
2021-05-19 |
Hutchinson Fred Cancer Res |
Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
|
|
WO2017161212A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
|
MA43758A
(fr)
|
2016-03-16 |
2018-11-28 |
Yuan Ji |
Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
|
|
RU2018136877A
(ru)
|
2016-03-22 |
2020-04-22 |
СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ) |
Способы раннего вмешательства для профилактики или улучшения состояния токсичности
|
|
US12144850B2
(en)
|
2016-04-08 |
2024-11-19 |
Purdue Research Foundation |
Methods and compositions for car T cell therapy
|
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
|
CN116850305A
(zh)
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
基因工程化细胞及其制备方法
|
|
JP2019517518A
(ja)
|
2016-06-03 |
2019-06-24 |
メモリアル スローン ケタリング キャンサー センター |
早期治療選択肢としての養子細胞療法
|
|
MX2018014911A
(es)
|
2016-06-06 |
2019-08-12 |
Juno Therapeutics Inc |
Metodos para el tratamiento de afecciones malignas de celulas t usando terapia de celulas adoptivas.
|
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
EP3475706B1
(de)
|
2016-06-27 |
2021-08-11 |
Juno Therapeutics, Inc. |
Mhc-e-beschränkte epitopen, bindungsmoleküle, und zugehörige verfahren und verwendungen
|
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
EP3269739A1
(de)
|
2016-07-15 |
2018-01-17 |
OGD2 Pharma |
Humanisierter antikörper gegen o-acetyliertes gd2-gangliosid (oacgd2)
|
|
US11186634B2
(en)
|
2016-07-29 |
2021-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies targeting tumor associated macrophages and uses thereof
|
|
CA3031955A1
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
EP3519433A1
(de)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-spezifische bindungsmoleküle
|
|
CA3040123A1
(en)
|
2016-10-11 |
2018-04-19 |
University Of Miami |
Vectors and vaccine cells for immunity against zika virus
|
|
ES2939646T3
(es)
|
2016-10-13 |
2023-04-25 |
Juno Therapeutics Inc |
Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
|
|
MA46783A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de type thérapie cellulaire t et inhibiteur de btk
|
|
CA3040914A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
|
AU2017367695A1
(en)
|
2016-12-02 |
2019-06-13 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
|
US20190358262A1
(en)
|
2016-12-03 |
2019-11-28 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
|
MA46995A
(fr)
|
2016-12-03 |
2019-10-09 |
Acerta Pharma Bv |
Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
|
|
MA46998A
(fr)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics Inc |
Production de cellules modifiées pour une thérapie cellulaire adoptive
|
|
JP7429338B2
(ja)
|
2017-01-10 |
2024-02-08 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法および関連方法のエピジェネティック解析
|
|
CA3050085A1
(en)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
WO2018148180A2
(en)
|
2017-02-07 |
2018-08-16 |
Immune Design Corp. |
Materials and methods for identifying and treating cancer patients
|
|
JP2020507605A
(ja)
|
2017-02-17 |
2020-03-12 |
フレッド ハッチンソン キャンサー リサーチ センター |
Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
|
|
CA3053539A1
(en)
|
2017-02-27 |
2018-08-30 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
EP3589654A1
(de)
|
2017-03-02 |
2020-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antikörper mit spezifität gegen nectin-4 und verwendungen davon
|
|
CN110831961B
(zh)
|
2017-03-03 |
2024-01-02 |
黑曜石疗法公司 |
用于免疫疗法的cd19组合物和方法
|
|
CN110913954A
(zh)
|
2017-03-03 |
2020-03-24 |
黑曜石疗法公司 |
免疫疗法的组合物和方法
|
|
AU2018235130B2
(en)
|
2017-03-15 |
2023-12-07 |
Oxford Biomedica (Uk) Limited |
Method
|
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
IL269553B2
(en)
|
2017-03-27 |
2025-10-01 |
Nat Univ Singapore |
Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
|
|
US11548930B2
(en)
|
2017-04-04 |
2023-01-10 |
Heat Biologics, Inc. |
Intratumoral vaccination
|
|
EP3385373A1
(de)
|
2017-04-05 |
2018-10-10 |
Centro de Neurociências e Biologia Celular |
Zusammensetzungen zur umprogrammierung von zellen in dendritischen zellen oder antigen-präsentierende zellen, verfahren und verwendungen davon
|
|
SG11201903353WA
(en)
|
2017-04-05 |
2019-05-30 |
Centro De Neurociencias E Biologia Celular |
Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
|
|
CA3056261A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
|
MA49288A
(fr)
|
2017-04-27 |
2020-03-04 |
Juno Therapeutics Gmbh |
Reactifs particulaires oligomères et leurs méthodes d'utilisation
|
|
KR20240139092A
(ko)
|
2017-05-01 |
2024-09-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법 및 면역조절 화합물의 조합
|
|
CN110662762A
(zh)
|
2017-05-24 |
2020-01-07 |
诺华股份有限公司 |
抗体细胞因子移植蛋白和用于治疗癌症的方法
|
|
CN111225675B
(zh)
|
2017-06-02 |
2024-05-03 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法治疗的制品和方法
|
|
AU2018275891B2
(en)
|
2017-06-02 |
2025-02-27 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
|
JP7388798B2
(ja)
|
2017-06-20 |
2023-11-29 |
アンスティテュート キュリー |
Ｓｕｖ３９ｈ１を欠損する免疫細胞
|
|
CN110914295B
(zh)
|
2017-06-28 |
2024-08-09 |
里珍纳龙药品有限公司 |
抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
|
|
TWI832820B
(zh)
|
2017-07-21 |
2024-02-21 |
美商伯克利之光生命科技公司 |
抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
|
|
AU2018313950A1
(en)
|
2017-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
CA3070575A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
|
US20210071258A1
(en)
|
2017-09-01 |
2021-03-11 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
|
MA50079A
(fr)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics Inc |
Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
|
|
WO2019054865A1
(en)
|
2017-09-14 |
2019-03-21 |
ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) |
T-cell based immunotherapy
|
|
EP3692063A1
(de)
|
2017-10-03 |
2020-08-12 |
Juno Therapeutics, Inc. |
Hpv-spezifische bindungsmoleküle
|
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
CN111527209B
(zh)
|
2017-11-01 |
2024-11-12 |
爱迪塔斯医药股份有限公司 |
Crispr-cas9编辑t细胞中的tgfbr2以用于免疫疗法的方法、组合物和组分
|
|
MX2020004572A
(es)
|
2017-11-01 |
2020-10-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
|
|
MA50859A
(fr)
|
2017-11-01 |
2020-09-09 |
Celgene Corp |
Procédé pour la production d'une composition de lymphocytes t
|
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
MA50855A
(fr)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Procédé de génération de compositions thérapeutiques de cellules modifiées
|
|
EP3706754A1
(de)
|
2017-11-06 |
2020-09-16 |
Juno Therapeutics, Inc. |
Kombination einer zelltherapie und eines gamma-sekretase-inhibitors
|
|
EP3707258A1
(de)
|
2017-11-06 |
2020-09-16 |
Editas Medicine, Inc. |
Verfahren, zusammensetzungen und komponenten zum crispr-cas9-editing von cblb in t-zellen zur immuntherapie
|
|
US11618884B2
(en)
|
2017-11-14 |
2023-04-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof
|
|
KR20200116081A
(ko)
|
2017-12-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포의 투약 및 조절 방법
|
|
EP3720480A2
(de)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Phänotypische marker für zelltherapie und verwandte verfahren
|
|
JP7433230B2
(ja)
|
2017-12-08 |
2024-02-19 |
ジュノー セラピューティクス インコーポレイテッド |
細胞を培養するための無血清培地配合物およびその使用の方法
|
|
CA3084445A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
EP4006153B1
(de)
|
2018-01-12 |
2024-07-03 |
Curocell Inc. |
Verbesserte immunzellen unter verwendung von dualer shrna und zusammensetzung damit
|
|
US11311576B2
(en)
|
2018-01-22 |
2022-04-26 |
Seattle Children's Hospital |
Methods of use for CAR T cells
|
|
WO2019152743A1
(en)
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
JP7470640B2
(ja)
|
2018-02-09 |
2024-04-18 |
イマティクス ユーエス，アイエヌシー． |
Ｔ細胞を製造する方法
|
|
CN111801348A
(zh)
|
2018-02-09 |
2020-10-20 |
新加坡国立大学 |
活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
|
DE102018108996B4
(de)
|
2018-02-09 |
2021-10-21 |
Immatics US, Inc. |
Verfahren zur Herstellung autologer T-Zellen
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
FI3755347T3
(fi)
|
2018-02-21 |
2025-07-29 |
Univ Texas |
Universaaleja antigeeniä esitteleviä soluja ja niiden käyttöjä
|
|
CA3091674A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
US20210023209A1
(en)
|
2018-03-16 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
US12098179B2
(en)
|
2018-03-16 |
2024-09-24 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
US12492230B2
(en)
|
2018-03-16 |
2025-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin V and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
WO2019183500A1
(en)
|
2018-03-23 |
2019-09-26 |
Hung Chiung Yu |
Coccidioides antigens and methods of their use
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
|
AU2019247199A1
(en)
|
2018-04-05 |
2020-10-15 |
Editas Medicine, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
EP3775238A1
(de)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
Verfahren zur herstellung von zellen, die einen rekombinanten rezeptor exprimieren, und verwandte zusammensetzungen
|
|
KR20210005646A
(ko)
|
2018-04-26 |
2021-01-14 |
아게누스 인코포레이티드 |
열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
|
|
JP7410877B2
(ja)
|
2018-05-03 |
2024-01-10 |
ジュノー セラピューティクス インコーポレイテッド |
キメラ抗原受容体（ｃａｒ）ｔ細胞療法とキナーゼ阻害剤の併用療法
|
|
US12343397B2
(en)
|
2018-05-17 |
2025-07-01 |
Regents Of The University Of Minnesota |
Drug-resistant immune cells and methods of use thereof
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
MX2021000532A
(es)
|
2018-07-19 |
2021-04-12 |
Regeneron Pharma |
Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
|
|
SG11202101204TA
(en)
|
2018-08-09 |
2021-03-30 |
Juno Therapeutics Inc |
Processes for generating engineered cells and compositions thereof
|
|
BR112021002245A2
(pt)
|
2018-08-09 |
2021-05-04 |
Juno Therapeutics Inc |
métodos para avaliar ácidos nucleicos integrados
|
|
BR112021003830A2
(pt)
|
2018-08-28 |
2021-07-20 |
Fred Hutchinson Cancer Research Center |
métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
|
|
EP3844186A4
(de)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
Verfahren zur spezifischen stimulation des überlebens und der expansion von genetisch modifizierten immunzellen
|
|
MX2021002316A
(es)
|
2018-08-31 |
2021-07-15 |
Invectys SA |
Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.
|
|
US20220047701A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
|
JP7320601B2
(ja)
|
2018-09-11 |
2023-08-03 |
上▲海▼市公共▲衛▼生▲臨▼床中心 |
広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
|
|
CA3112813A1
(en)
|
2018-09-21 |
2020-03-26 |
Berkeley Lights, Inc. |
Functionalized well plate, methods of preparation and use thereof
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
SG11202103296RA
(en)
|
2018-10-18 |
2021-05-28 |
Berkeley Lights Inc |
Proto-antigen-presenting synthetic surfaces, activated t cells, and uses thereof
|
|
EA202191107A1
(ru)
|
2018-10-23 |
2021-09-17 |
Ридженерон Фармасьютикалз, Инк. |
T-клеточные рецепторы ny-eso-1 и способы их применения
|
|
EP3874024A1
(de)
|
2018-10-31 |
2021-09-08 |
Juno Therapeutics GmbH |
Verfahren zur selektion und stimulation von zellen und vorrichtung dafür
|
|
SG11202104188VA
(en)
|
2018-11-01 |
2021-05-28 |
Juno Therapeutics Inc |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
MX2021005022A
(es)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
|
|
JP7604366B2
(ja)
|
2018-11-06 |
2024-12-23 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作されたｔ細胞を作製するための方法
|
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
|
EP3880238A1
(de)
|
2018-11-16 |
2021-09-22 |
Juno Therapeutics, Inc. |
Verfahren zur dosierung von manipulierten t-zellen zur behandlung von b-zell-malignitäten
|
|
CA3120563A1
(en)
|
2018-11-26 |
2020-06-04 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
SG11202105380RA
(en)
|
2018-11-30 |
2021-06-29 |
Juno Therapeutics Inc |
Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
|
|
BR112021010354A2
(pt)
|
2018-11-30 |
2021-11-03 |
Juno Therapeutics Inc |
Métodos para o tratamento usando terapia celular adotiva
|
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
|
EP3914719A4
(de)
|
2019-01-24 |
2023-04-05 |
Valorisation-HSJ, Limited Partnership |
Zellspezifische transkriptionsregulationssequenzen und deren verwendungen
|
|
CA3123303A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
KR20210149251A
(ko)
|
2019-03-08 |
2021-12-08 |
옵시디안 테라퓨틱스, 인크. |
조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
|
|
WO2020191172A1
(en)
|
2019-03-19 |
2020-09-24 |
Immatics US, Inc. |
Cd28 t cell cultures, compositions, and methods of using thereof
|
|
DE102019108125B4
(de)
|
2019-03-28 |
2022-02-03 |
Immatics US, Inc. |
Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
|
|
US12404331B2
(en)
|
2019-04-19 |
2025-09-02 |
Tcrcure Biopharma Corp. |
Anti-PD-1 antibodies and uses thereof
|
|
MX2021013223A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
|
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
|
AU2020273471B2
(en)
|
2019-05-14 |
2026-05-07 |
The University Of Chicago |
Methods and compositions comprising Staphylococcus protein A (SpA) variants
|
|
EP3969569A1
(de)
|
2019-05-14 |
2022-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Durch lymphotoxin-alpha-blockierungsmittel angezielte regulatorische t-zellen und verwendungen davon
|
|
JP2022537670A
(ja)
|
2019-06-12 |
2022-08-29 |
オブシディアン セラピューティクス， インコーポレイテッド |
Ｃａ２の組成物および調整可能な制御方法
|
|
US20220249637A1
(en)
|
2019-06-12 |
2022-08-11 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
|
WO2020252404A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
EP3994245A1
(de)
|
2019-07-05 |
2022-05-11 |
Case Western Reserve University |
Priming-medium und verfahren für stammzellenkultur und -therapie
|
|
JP7753184B2
(ja)
|
2019-07-16 |
2025-10-14 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） |
Ｃｄ３８に特異性を有する抗体及びその使用
|
|
US20220251572A1
(en)
|
2019-07-23 |
2022-08-11 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
US12600793B2
(en)
|
2019-07-24 |
2026-04-14 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with MAGE-A4 specificity and uses thereof
|
|
CN114555112A
(zh)
|
2019-08-22 |
2022-05-27 |
朱诺治疗学股份有限公司 |
T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
MX2022002747A
(es)
|
2019-09-10 |
2022-04-06 |
Obsidian Therapeutics Inc |
Proteinas de fusion de ca2-il15 para regulacion ajustable.
|
|
US12528882B2
(en)
|
2019-09-13 |
2026-01-20 |
The University Of Chicago |
Methods and compositions for treating staphylococcal infections
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
EP4041867A1
(de)
|
2019-10-09 |
2022-08-17 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
T-zellen, die so modifiziert sind, dass sie mutiertes cxcr4 exprimieren oder teilweise deletiert sind, und verwendungen davon
|
|
CA3154281A1
(en)
|
2019-10-16 |
2021-04-22 |
Andrew Scharenberg |
Retroviral vector for universal receptor therapy
|
|
WO2021084050A1
(en)
|
2019-10-30 |
2021-05-06 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
|
AU2020379848A1
(en)
|
2019-11-06 |
2022-05-19 |
Baylor College Of Medicine |
Method for producing cytotoxic effector memory T cells for T-cell treatment of cancer
|
|
IL292667B1
(en)
|
2019-11-07 |
2026-02-01 |
Juno Therapeutics Inc |
Combination of T-cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2-dione
|
|
CA3156954A1
(en)
|
2019-11-25 |
2021-06-03 |
Asgard Therapeutics Ab |
Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof
|
|
WO2021113770A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
|
|
US12577324B2
(en)
|
2019-12-09 |
2026-03-17 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity to HER4 and uses thereof
|
|
MX2022008415A
(es)
|
2020-01-08 |
2022-08-08 |
Obsidian Therapeutics Inc |
Composiciones y metodos para la regulacion ajustable de la transcripcion.
|
|
IL294988A
(en)
|
2020-01-24 |
2022-09-01 |
Regeneron Pharma |
Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
|
|
KR20220145341A
(ko)
|
2020-01-24 |
2022-10-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법에서 여포성 림프종 및 변연부 림프종의 투여 및 치료 방법
|
|
KR20220146480A
(ko)
|
2020-01-28 |
2022-11-01 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｔ 세포 형질도입 방법
|
|
IL295381B1
(en)
|
2020-02-12 |
2026-04-01 |
Juno Therapeutics Inc |
BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
|
|
WO2021173674A1
(en)
|
2020-02-26 |
2021-09-02 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
|
US20210322471A1
(en)
|
2020-03-27 |
2021-10-21 |
Dcprime B.V. |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
IL297147B1
(en)
|
2020-04-10 |
2026-05-01 |
Juno Therapeutics Inc |
Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
|
|
CN116157125A
(zh)
|
2020-04-28 |
2023-05-23 |
朱诺治疗学股份有限公司 |
针对bcma的t细胞疗法与免疫调节化合物的组合
|
|
JP7648654B2
(ja)
|
2020-05-05 |
2025-03-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ２８ゼータ及びｃｄ３ゼータを含むｃａｒ
|
|
KR20230008751A
(ko)
|
2020-05-12 |
2023-01-16 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
|
|
WO2021231657A1
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
|
IL298558A
(en)
|
2020-05-27 |
2023-01-01 |
Antion Biosciences Sa |
Adapter molecules redirect CAR T cells to the antigen of interest
|
|
CN116157510A
(zh)
|
2020-06-17 |
2023-05-23 |
詹森生物科技公司 |
用于制造多能干细胞的材料和方法
|
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
KR20230033647A
(ko)
|
2020-06-30 |
2023-03-08 |
멘두스 비.브이. |
난소암 백신에서 백혈병 유래 세포의 용도
|
|
CN116323656A
(zh)
|
2020-07-16 |
2023-06-23 |
优莫佳生物制药股份有限公司 |
门控衔接子靶向受体
|
|
WO2022012680A1
(en)
|
2020-07-16 |
2022-01-20 |
Nanjing Legend Biotech Co., Ltd. |
Cd20 binding molecules and uses thereof
|
|
CN116490518A
(zh)
|
2020-07-17 |
2023-07-25 |
西穆尔克斯股份有限公司 |
用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
|
|
CN116096864A
(zh)
|
2020-07-30 |
2023-05-09 |
居里研究所 |
Socs1缺陷的免疫细胞
|
|
EP4189071A1
(de)
|
2020-08-03 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Population von treg-zellen, die funktionell mit einer regulatorischen aktivität behaftet sind, und ihre verwendung zur adoptiven therapie
|
|
EP4097486A4
(de)
|
2020-08-20 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von ceacam-positivem krebs
|
|
EP4058474B1
(de)
|
2020-08-20 |
2024-05-08 |
A2 Biotherapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von egfr-positiven karzinomen
|
|
WO2022040454A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
CN116546992A
(zh)
|
2020-08-21 |
2023-08-04 |
12343096 加拿大公司 |
模块化组装受体及其用途
|
|
US20220056411A1
(en)
|
2020-08-21 |
2022-02-24 |
Immatics US, Inc. |
Methods for isolating cd8+ selected t cells
|
|
US20240141295A1
(en)
|
2020-08-31 |
2024-05-02 |
City Of Hope |
Novel cell lines, methods of producing natural killer cells and uses thereof
|
|
WO2022060904A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
WO2022074098A1
(en)
|
2020-10-08 |
2022-04-14 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Method for the identification of cancer neoantigens
|
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
WO2022097068A1
(en)
|
2020-11-05 |
2022-05-12 |
Dcprime B.V. |
Use of tumor-independent antigens in immunotherapies
|
|
EP4251282A1
(de)
|
2020-11-27 |
2023-10-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur diagnose und überwachung von toxischer epidermaler nekrolyse
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
AU2022211682A1
(en)
|
2021-01-22 |
2023-08-03 |
Mendus B.V. |
Methods of tumor vaccination
|
|
JP2024504875A
(ja)
|
2021-02-01 |
2024-02-01 |
▲い▼尊生物医薬（浙江）有限公司 |
標的タンパク質分解システムおよびその応用
|
|
WO2022177979A1
(en)
|
2021-02-16 |
2022-08-25 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating her2 positive cancers
|
|
WO2022187406A1
(en)
|
2021-03-03 |
2022-09-09 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
AU2022252220A1
(en)
|
2021-03-29 |
2023-10-12 |
Juno Therapeutics, Inc. |
Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
|
|
WO2022221726A2
(en)
|
2021-04-16 |
2022-10-20 |
Juno Therapeutics, Inc. |
Combination therapies with bcma-directed t cell therapy
|
|
JP2024516308A
(ja)
|
2021-05-04 |
2024-04-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｍａｇｅ－ａ４特異性を有するキメラ抗原受容体及びその使用
|
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
|
US20250304915A1
(en)
|
2021-05-25 |
2025-10-02 |
Institut Curie |
Myeloid Cells Overexpressing BCL2
|
|
WO2023006120A1
(zh)
|
2021-07-30 |
2023-02-02 |
羿尊生物医药（浙江）有限公司 |
通用型t细胞及其应用
|
|
WO2023044488A1
(en)
|
2021-09-20 |
2023-03-23 |
Immatics US, Inc. |
Monocyte depletion of t cells populations for t-cell therapy
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
EP4433512A4
(de)
|
2021-11-19 |
2025-12-31 |
Univ Pennsylvania |
Manipuliertes pan-leukozytenantigen cd45 zur erleichterung der car-t-zelltherapie
|
|
EP4456910A1
(de)
|
2021-12-28 |
2024-11-06 |
Mnemo Therapeutics |
Immunzellen mit inaktiviertem suv39h1 und modifiziertem tcr
|
|
CN120077132A
(zh)
|
2022-01-21 |
2025-05-30 |
姆内莫治疗公司 |
Rna对suv39h1表达的调控
|
|
CA3251397A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
METHODS AND COMPOSITIONS COMPRISING COMPONENTS FOR BRINGING BISORPOSE VΒ17 T LYMPHOCYTES TO CONTACT WITH BIOMODIFIED VIRUS-SPECIFIC LYMPHOCYTES
|
|
EP4479143A1
(de)
|
2022-02-18 |
2024-12-25 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verwendung von tcr-defizienten car-tregs in kombination mit monoklonalen anti-tcr-komplex-antikörpern zur induzierung von dauerhafter toleranz
|
|
EP4482519A1
(de)
|
2022-02-22 |
2025-01-01 |
Juno Therapeutics, Inc. |
Chimäre autoantikörper-rezeptor-t-zellen aus proteinase 3 (pr3) und zugehörige verfahren und verwendungen
|
|
MX2024010015A
(es)
|
2022-02-22 |
2024-08-22 |
Deka Biosciences Inc |
Metodo para reducir el sindrome de liberacion de citosinas mediado por celulas t del receptor de antigeno quimerico o el activador de celulas t biespecificas usando interleucinas.
|
|
JP2025508076A
(ja)
|
2022-03-08 |
2025-03-21 |
アレンティス・セラピューティクス・アクチェンゲゼルシャフト |
Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4279085A1
(de)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Zusammensetzungen und verfahren zum behandeln eines refraktären oder rezidivierenden krebses oder einer chronischen infektionskrankheit
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
EP4532695A1
(de)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Verfahren zur herstellung von t-zelltherapien
|
|
WO2023237663A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
|
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
WO2024019984A1
(en)
|
2022-07-18 |
2024-01-25 |
Cargo Therapeutics, Inc. |
Cytokine receptor switch polypeptides and uses thereof
|
|
US20250188492A1
(en)
|
2022-07-22 |
2025-06-12 |
Janssen Biotech, Inc. |
Enhanced Transfer of Genetic Instructions to Effector Immune Cells
|
|
CN120051298A
(zh)
|
2022-08-05 |
2025-05-27 |
朱诺治疗学股份有限公司 |
Gprc5d和bcma特异性嵌合抗原受体
|
|
JP2025529903A
(ja)
|
2022-08-26 |
2025-09-09 |
ジュノー セラピューティクス インコーポレイテッド |
デルタ様リガンド３（ｄｌｌ３）に特異的な抗体およびキメラ抗原受容体
|
|
EP4580658A1
(de)
|
2022-08-31 |
2025-07-09 |
Institut National de la Santé et de la Recherche Médicale |
Verfahren zur erzeugung effizienterer car-t-zellen
|
|
EP4583905A1
(de)
|
2022-09-06 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Neuartige car-t-doppelspaltzellen zur behandlung von cd38-positiven hämatologischen malignomen
|
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
JP2025531832A
(ja)
|
2022-09-08 |
2025-09-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ＬＴＢＰ２（潜在的形質転換増殖因子β結合タンパク質２）に対する特異性を有する抗体及びその使用
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
|
WO2024091944A1
(en)
|
2022-10-25 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Split receptor switch polypeptides and uses thereof
|
|
WO2024092092A2
(en)
|
2022-10-27 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Compositions and methods for allogeneic immunotherapies
|
|
EP4608856A1
(de)
|
2022-10-27 |
2025-09-03 |
CARGO Therapeutics, Inc. |
Zusammensetzungen und verfahren für verbesserte immuntherapien
|
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
WO2024123760A1
(en)
|
2022-12-05 |
2024-06-13 |
Cargo Therapeutics, Inc. |
Multiplex cell selection compositions and uses thereof
|
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
WO2024168276A2
(en)
|
2023-02-09 |
2024-08-15 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|
|
EP4687959A1
(de)
|
2023-03-24 |
2026-02-11 |
Cornell University |
Verwendung von t-zellen aus tumordränierenden lymphknoten zur chimären antigenrezeptor(car)-t-zelltherapie zur behandlung von krebs
|
|
EP4698902A1
(de)
|
2023-04-18 |
2026-02-25 |
Juno Therapeutics, Inc. |
Zytotoxizitätstest zur beurteilung der wirksamkeit von therapeutischen zellzusammensetzungen
|
|
EP4702132A1
(de)
|
2023-04-26 |
2026-03-04 |
Institut National de la Santé et de la Recherche Médicale |
Verfahren zur modulation der differenzierung und funktionen menschlicher dendritischer zellen
|
|
WO2024243511A1
(en)
|
2023-05-25 |
2024-11-28 |
Regeneron Pharmaceuticals, Inc. |
T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides
|
|
WO2025029930A1
(en)
|
2023-07-31 |
2025-02-06 |
Legend Biotech Ireland Limited |
Cells overexpressing cd31 and methods of use thereof
|
|
WO2025049972A1
(en)
|
2023-09-01 |
2025-03-06 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|
|
WO2025059362A1
(en)
|
2023-09-13 |
2025-03-20 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025076472A1
(en)
|
2023-10-06 |
2025-04-10 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025085680A1
(en)
|
2023-10-17 |
2025-04-24 |
Cargo Therapeutics, Inc. |
Methods for manufacturing car t cells
|
|
WO2025082603A1
(en)
|
2023-10-18 |
2025-04-24 |
Institut Curie |
Engineered immune cells overexpressing cd74 molecule
|
|
WO2025090978A1
(en)
|
2023-10-26 |
2025-05-01 |
Cargo Therapeutics, Inc. |
Modified immune effector cells
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
WO2025125363A1
(en)
|
2023-12-11 |
2025-06-19 |
Institut National de la Santé et de la Recherche Médicale |
Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions
|
|
WO2025129084A1
(en)
|
2023-12-13 |
2025-06-19 |
Umoja Biopharma, Inc. |
Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025245381A1
(en)
|
2024-05-23 |
2025-11-27 |
The Trustrees Of Dartmouth College |
Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
|
|
WO2025255030A1
(en)
|
2024-06-03 |
2025-12-11 |
Cornell University |
Interferon gamma responsive chimeric t cell costimulatory receptor
|
|
WO2026002973A1
(en)
|
2024-06-25 |
2026-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Host immune cells engineered to overexpress a foxk1 polypeptide
|
|
WO2026035951A2
(en)
|
2024-08-07 |
2026-02-12 |
Legend Biotech Ireland Limited |
Cells overexpressing cd43 and methods of use thereof
|
|
WO2026055226A1
(en)
|
2024-09-03 |
2026-03-12 |
Legend Biotech Ireland Limited |
Cells overexpressing b3gnt2 and methods of use thereof
|
|
CN121896173A
(zh)
|
2024-10-21 |
2026-04-21 |
深圳市湾岛细胞科技有限公司 |
表达外源肌苷单磷酸脱氢酶的真核细胞
|